Arsenal Biosciences
Programmable CAR-T company using logic gates so cells fire only when two tumour proteins are present; AB-2100 (PSMA + CA9) is in phase 1/2 for kidney cancer.
AB-2100 uses a synthetic AND gate (PSMA and CA9), shRNA armouring against TME suppression, and a synthetic pathway activator; phase 1/2 in clear-cell RCC after IO and VEGF therapy (NCT06245915, primary completion 2026). AB-1015 in ovarian cancer. Raised $325M with Regeneron and BMS participation.
Pages like this
not linked directly; found by shared links- TechnologyMasked / conditionally active ADC
Shares Logic-gated therapeutics (AND, NOT gates) and the tag frontier.
- CompanyGenerate:Biomedicines
Shares Ovarian cancer, CAR-T cell therapy and the tag frontier.
- TechnologyRadio-antibody & radio-ADC
Shares PSMA, Renal cell carcinoma and the tag frontier.
- TechnologyBispecific ADC
Shares Logic-gated therapeutics (AND, NOT gates), Bristol Myers Squibb and the tag frontier.
- TechnologyIn vivo CAR-T
Shares Logic-gated therapeutics (AND, NOT gates), CAR-T cell therapy and the tag frontier.
- TechnologyCAR-NK & CAR-macrophage
Shares CAR-T cell therapy and the tag frontier.
- TechnologyTargeted alpha therapy
Shares PSMA and the tag frontier.
- TechnologyCAR-T against stroma: fibroblasts and myeloid cells
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy and the tag frontier.